SCHEMBL25656349

SCHEMBL25656349

CCOC(=O)c1cnc2cc(C(C)=O)c(C(C)=O)cc2c1C

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
MAPK1 P28482 3/20 0.44
MAPT P10636 4/20 0.44
GAA P10253 2/20 0.43
NPC1 O15118 1/20 0.43
POLB P06746 1/20 0.43
PKM P14618 1/20 0.43
DPP4 P27487 2/20 0.43
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 2/20 0.42
ATM Q13315 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
LMNA P02545 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TP53 P04637 1/20 0.42
AURKA O14965 1/20 0.42
AURKB Q96GD4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19020859 0.80 CA2 (0.55) KMT2AMEN1MAPK1MAPTGAA
SCHEMBL20799490 0.79 LMNA (0.60) KMT2AMEN1MAPK1MAPTPOLB
SCHEMBL15445432 0.77 KMT2A (0.64) KMT2AMEN1MAPK1MAPTGAA
SCHEMBL1644640 0.76 THRB (0.50) KMT2AMEN1MAPK1MAPTGAA
SCHEMBL14378112 0.75 THRB (0.62) KMT2AMEN1MAPTNPC1KDM4E
SCHEMBL1467061 0.73 MEN1 (0.62) KMT2AMEN1MAPK1MAPTGAA
SCHEMBL19021463 0.73 MAPK1 (0.44) KMT2AMEN1MAPK1MAPTGAA
SCHEMBL5929779 0.72 KMT2A (0.54) KMT2AMEN1MAPK1MAPTGAA
SCHEMBL1467265 0.72 KMT2A (0.61) KMT2AMEN1MAPK1MAPTGAA
SCHEMBL25656120 0.71 KMT2A (0.53) KMT2AMEN1MAPK1MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183212-A1 INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF STINGRAY THERAPEUTICS INC (US) 2023-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183212-A1 INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF ENPP1, ENPP3, PPA1 KMT2A 4288/4885MEN1 796/4885MAPK1 984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.